20单核苷酸多态性与美罗华耐药没有相关性但却是弥漫大B细胞淋巴瘤的易感位点

he integral membrane protein CD20 has been identified as an important target in the treatment of B-cell non-Hodgkin lymphoma. The purpose of this study was to explore whether there are polymorphisms in CD20 that could be associated with tumorigenesis, prognosis, and rituximab resistance. We sequenced exons 3-8 in 170 patients with de novo B-cell non-Hodgkin lymphoma and detected the expression of CD20 via immunohistochemistry. Clinical and laboratory parameters were compared between the patients with and without polymorphisms using a chi-square test. The Kaplan-Meier method was used to construct survival curves, and results were compared using a log-rank test. We found two SNPs: rs17155019 in the 5' untranslated region and rs2070770 (ILE72/ILE72) in exon 4. The C/T and T/T genotypic frequencies of rs2070770 were significantly higher in patients with diffuse large B-cell lymphoma (DLBCL) than in healthy adults (P=0.013). The risk of DLBCL was significantly higher in T allele carriers of rs2070770 than in C allele carriers (odds ratio=3.314; 95% confidence interval 2.295-4.787; P<0.001). DLBCL patients who were T allele carriers of rs2070770 tended to have normal serum ferritin level and a lower international prognostic index (IPI≤3) than C allele carriers (P=0.036 and 0.014, respectively). However, neither SNP seemed to have a significant impact on survival in patients with DLBCL. SNPs of CD20 might not be a prognostic factor for patients with DLBCL and do not contribute to resistance to rituximab but may be a DLBCL susceptibility locus.